Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | genetic association 0.92 (overall 0.87) | 0.92 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: prasinezumab, cinpanemab | 0.81 |
| trials ClinicalTrials.gov | 135 Parkinson's trials, 6 stopped | 0.90 |
| literature PubMed | 1,886 Parkinson's papers of 2,110: well-trodden | 0.01 |
| pathways Reactome | Reactome did not answer (Reactome: HTTP 521) | 0.00 |
No case: the score is under the bar. Receipt 12546
Earlier readings: 2026-10-27 0.57; 2026-10-26 0.57; 2026-10-25 0.57; 2026-10-24 0.57.
Sealed predictions
- SNCA in astrocytes, braak+0.65 (p 0.058) → +0.32 (p 0.400)receipt 11037
- SNCA in microglia, braak+0.01 (p 0.982) → -0.36 (p 0.347)receipt 10879
- SNCA in dopamine neurons, braak-0.25 (p 0.517) → +0.44 (p 0.232)receipt 0510
- SNCA in dopamine neurons, resilience+0.08 (p 0.739) → -0.18 (p 0.616)receipt 0008
- SNCA in dopamine neurons, braak-0.04 (p 0.780) → -0.15 (p 0.350)receipt 0007
In the sealed studies
- The synaptic vesicle cycle in resilient donors: did not hold
Swarm cases
receipt 0510: SNCA in dopamine neurons, braak
- power
- full sample +0.21 (p 0.408, n 18), 95% CI -0.29 to +0.61. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.23 (p 0.365, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.26 (p 0.306, n 18). could be the mix.
- skeptic
- leave-one-out range +0.12 to +0.32, sign flips 0; without severely affected donors +0.21 (p 0.408, n 18). fragile.
- cell type
- strongest in oligodendrocytes: +0.66 (p 0.0030, n 18) vs +0.21 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SNCA in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up SNCA · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.73 p 0.0100 (needs p < 0.0016)
receipt 0008: SNCA in dopamine neurons, resilience
- power
- full sample +0.08 (p 0.689, n 55), 95% CI -0.19 to +0.34. the interval is wide: not enough donors to tell.
- confounder
- adjusted for age, sex and PMI: +0.08 (p 0.674, n 55). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.12 (p 0.542); controlling for it: +0.09 (p 0.643, n 55). could be the mix.
- skeptic
- leave-one-out range -0.01 to +0.18, sign flips 2; without severely affected donors +0.10 (p 0.616, n 46). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "differs in resilient donors (Lewy pathology, no parkinsonism)" for SNCA in dopamine neurons.
case closed: nothing better to follow up.
receipt 0007: SNCA in dopamine neurons, braak
- power
- full sample -0.08 (p 0.456, n 84), 95% CI -0.29 to +0.13. the interval sits on zero: probably nothing there.
- confounder
- adjusted for age, sex and PMI: -0.05 (p 0.654, n 84). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis -0.72 (p 1.8e-14); controlling for it: -0.04 (p 0.748, n 84). could be the mix.
- skeptic
- leave-one-out range -0.12 to -0.06, sign flips 0; without severely affected donors -0.12 (p 0.292, n 75). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SNCA in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts